← All indications
Pulmonary Emphysema
Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.
Drugs by status
Phase 4 trials (3)
Phase 2 trials (3)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (15)
- CSL Behring
- Merck
- Sunovion
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- Cairo University
- Johns Hopkins University
- University of East Anglia
- University of Iowa
- University of California, Los Angeles
- Leiden University
- University of Amsterdam
- University of Sao Paulo
- Noordwest Ziekenhuisgroep
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (25)
- Roche
- Pfizer
- Aeris Therapeutics
- Gerard Turino
- University of Pennsylvania
- University of Florida
- University of Miami
- University of Nebraska
- University of Rochester
- Columbia University
- Peking University
- University of Colorado, Denver
- University of Copenhagen
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- Mesoblast, Inc.
- Government of China
- University of Alabama, Birmingham
- University of Texas, Tyler
- Pulmonary Associates, Phoenix, AZ
- St Joseph's Medical Center, Towson, MD
- Veritas Clinical Specialties, Topeka, KS
- Alpha-1 Foundation
- Stony Wold-Herbert Fund, Inc.
- The Cleveland Clinic
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (3)